- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EPIMINDER Aktie jetzt für 0€ handeln | |||||
| Di | EPIMINDER LIMITED: Becoming a substantial holder | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Becoming a substantial holder | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Initial Director's Interest Notice | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Initial Director's Interest Notice | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Initial Director's Interest Notice | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Initial Director's Interest Notice | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Initial Director's Interest Notice | 2 | ASX | ||
| Di | EPIMINDER LIMITED: Becoming a substantial holder | 1 | ASX | ||
| Di | EPIMINDER LIMITED: Epiminder Listing and Business Update | 1 | ASX | ||
| 27.11. | EPIMINDER LIMITED: Pre-Quotation Disclosure | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Top 20 Holders | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Distribution Schedule | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Securities Trading Policy | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Employee Share Option Plan | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Corporate Governance Statement | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Audited Accounts FY2025 | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Audited Accounts FY2024 | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Constitution | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Prospectus | - | ASX | ||
| 27.11. | EPIMINDER LIMITED: Information Form and Checklist | - | ASX |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,340 | -1,37 % | Neue 3,250%-Anleihe von Fresenius Medical Care | Stuttgart (www.anleihencheck.de) - Fresenius Medical Care (ISIN DE0005785802/ WKN 578580) hat eine Unternehmensanleihe (ISIN XS3233499089/ WKN A460DH) mit einem Volumen von bis zu 500 Millionen Euro... ► Artikel lesen | |
| FRESENIUS | 47,210 | +0,75 % | DZ BANK stuft Fresenius SE auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Aktienwert für Fresenius nach den Anfang November vorgelegten Zahlen zum dritten Quartal von 56 auf 57 Euro angehoben. Die Einstufung wurde... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 42,370 | -0,35 % | PRESSESPIEGEL/Unternehmen: SIEMENS HEALTHINEERS, INSTONE, BÖRSE STUTTGART, VOLKSWAGEN | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
SIEMENS HEALTHINEERS - Das größte Potenzial sieht Siemens-Healthineers-CEO... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 33,180 | +12,36 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| GENEDX | 160,38 | -0,14 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,100 | +0,05 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| PROGYNY | 24,550 | -1,60 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| KESTRA MEDICAL TECHNOLOGIES | 25,840 | +12,20 % | Kestra Medical Technologies, Ltd.: Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results | KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial... ► Artikel lesen | |
| BETA BIONICS | 30,400 | +6,89 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,110 | -0,09 % | BMO Capital Maintains Bullish 12%+ BrightSpring EBITDA Growth Outlook on Drug Contract Wins, Generic Conversions | ||
| GERRESHEIMER | 26,280 | +2,58 % | Gold, Drohnen und Spezialglas! Einfach mal 200 % aus dem Stand mit DroneShield, AJN Resources und Gerresheimer | Die Börse zeigt sich von der volatilen Seite. Während KI-, Rüstungs- und Tech-Aktien auch mal konsolidieren, schießen Gold und Silber durch die Decke. Die Branchenrotation ist zum Jahresende also voll... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 42,840 | -0,23 % | RBC stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 47 Euro auf "Sector Perform" belassen. Analyst Jack Reynolds-Clark geht skeptisch... ► Artikel lesen | |
| BILLIONTOONE | 102,76 | -10,64 % | BillionToOne, Inc.: BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025 | ||
| PRIVIA HEALTH GROUP | 24,300 | +1,25 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| PACS GROUP | 31,370 | 0,00 % | PACS Group, Inc. - 8-K, Current Report |
EPIMINDER LIMITED gehört der Branche Gesundheitswesen an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EPIMINDER LIMITED finden Sie auf Wallstreet Online.